Vimarsana
Biggest News Aggregation in the World

Page 27 - Pharma Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pharma Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pharma Group Today - Breaking & Trending Today

China Approves World's First Denosumab Biosimilar | Goodwin - Vimarsana News

China Approves World's First Denosumab Biosimilar | Goodwin

​​​​​​​Luye Pharma Group announced last week that China’s National Medical Products Administration has approved a marketing launch of BOYOBEI® for treatment of postmenopausal women with...

Lo.Li. Pharma International: Pervistop, the once-daily supplement specifically designed to manage persistent HPV, is now available for exclusive distribution rights worldwide. - Vimarsana News

Lo.Li. Pharma International: Pervistop, the once-daily supplement specifically designed to manage persistent HPV, is now available for exclusive distribution rights worldwide.

Lo.Li. Pharma International to unveil an innovative new product at CPHI Frankfurt, which has already gained the interest of numerous distribution partners. Pervistop promises to be an extremely

Pervistop®, the once-daily supplement specifically designed to manage persistent HPV, is now available for exclusive distribution rights worldwide. - Vimarsana News

Pervistop®, the once-daily supplement specifically designed to manage persistent HPV, is now available for exclusive distribution rights worldwide.

/PRNewswire/ -- Lo.Li. Pharma International announces the pre-launch of a new, highly anticipated product at CPHI 2022, fulfilling a latent unmet clinical need...

Investegate |Covis Pharma Announcements | Covis Pharma: Covis Pharma Announces Positive Topline Results from the AVANT Phase 3 Clinical Trial Showing Significant Improvement in Patients with Moderate to Severe Stable COPD - Vimarsana News

Investegate |Covis Pharma Announcements | Covis Pharma: Covis Pharma Announces Positive Topline Results from the AVANT Phase 3 Clinical Trial Showing Significant Improvement in Patients with Moderate to Severe Stable COPD

Investegate announcements from Covis Pharma, Covis Pharma Announces Positive Topline Results from the AVANT Phase 3 Clinical Trial Showing Significant Improvement in Patients with Moderate to Severe Stable COPD

Covis Pharma Announces Positive Topline Results from the AVANT Phase 3 Clinical Trial Showing Significant Improvement in Patients with Moderate to Severe Stable COPD - Vimarsana News

Covis Pharma Announces Positive Topline Results from the AVANT Phase 3 Clinical Trial Showing Significant Improvement in Patients with Moderate to Severe Stable COPD

ZUG, Switzerland, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Covis Pharma Group ("Covis"), a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions